Early phase 1Recruiting
Pain Sensitivity, Alcohol-Induced Analgesia, and Heavy Drinking in Individuals With Opioid Use Disorder
- Sponsor
- Ohio State University (Academic or other)
- Enrollment
- 90 planned
- Conditions
- Opioid Use Disorder; Alcohol Intoxication; Pain
- Interventions
- Alcohol; Placebo
- Ages
- adults, older adults
- Registry
- NCT07894276
Full record on ClinicalTrials.gov
From the registry
The goal of this clinical trial is to examine whether individuals with co-occurring opioid use disorder and alcohol use (OUD+ALC) experience heightened pain sensitivity, pain-related negative affect, and greater alcohol reinforcement compared with alcohol-only (ALC) or opioid-only (OUD-ALC) users. The main questions it aims to answer are: * Aim 1. Do individuals with OUD+ALC experience increased pain and pain-related negative affect during periods of sobriety relative to mono-users of alcohol (ALC only) and opioids (OUD-ALC)? * Aim 2. Do individuals with OUD+ALC experience greater alcohol-induced analgesia and alcohol reinforcement compared with mono-users of alcohol (ALC only) and opioids (OUD-ALC)? Participants will: * Complete a screening session * Complete one lab session including a comprehensive assessment battery involving multimodal assessments of pain during sobriety * Complete two experimental lab sessions that will include intravenous (IV) administration of either 80mg% alcohol or placebo (saline), order counterbalanced, to measure alcohol's acute effects on pain and…
Primary outcomes
- Pain intensity during the pressure task, measured using a visual analog scale (VAS)
- Pain pressure threshold during the pressure task
- Startle eyeblink potentiation during the anticipation task
- Self-reported affect during the anticipation task
History
Primary completion expected
Last registry update
Started
Registered
In the news
ResearchJAMA (opens JAMA in a new tab)
44% of drinkers report drinking less after starting glucagon-like peptide-1 receptor agonists
The JAMA Psychiatry survey included about 2,000 adults, with more than 200 drinking at treatment initiation, and assessed consumption during the first three months.
ResearchMedical Xpress (opens Medical Xpress in a new tab)
Model finds liver cancer screening cost-effective at 0.45% annual risk in alcohol-associated cirrhosis
Mass General Brigham researchers modeled 50 million hypothetical U.S. patients, estimating 2,083 additional life-years per 100,000 active drinkers and 3,357 among abstinent patients with six-monthly screening.

